Effects of cantharidin on force of contraction and phosphatase activity in nonfailing and failing human hearts

British Journal of Pharmacology

Volumn 119, Issue 3, 1996, Pages 545-550

  Linck, Bettina ^a   Boknik, Peter ^a   Knapp, Jörg ^a   Müller, Frank U ^a   Neumann, Joachim ^a   Schmitz, Wilhelm ^a   Vahlensieck, Ute ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Cantharidin; Contractility; Human myocardium; Phosphatase activity

Indexed keywords

CANTHARIDIN; INOTROPIC AGENT; ISOPRENALINE; PHOSPHATASE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; HEART FAILURE; HEART MUSCLE CONTRACTILE FORCE; HUMAN; HUMAN TISSUE; INOTROPISM; PRIORITY JOURNAL;

EID: 0029789134     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb15706.x     Document Type: Article

References (21)

1. AHMAD, Z., GREEN, F.J., SUBUHI, H.S. & WATANABE, A.M. (1989). Autonomic regulation of type 1 protein phosphatase in cardiac muscle. J. Biol. Chem., 264, 3859-3863.
2. BARTEL, S., STEIN, B., ESCHENHAGEN, T., MENDE, U., NEUMANN, J., SCHMITZ, W., KRAUSE, E.G. KARCZEWSKI, P. & SCHOLZ, H. (1996). Impaired phosphorylation of phospholamban and troponin I in the failing human heart. Mol. Cell. Biochem., (in press).
3. BÖHM, M., REIGER, B., SCHWINGER, R.H. & ERDMANN, E. (1994). cAMP concentrations, cAMP dependent protein kinase activity, and phospholamban in nonfailing and failing myocardium. Cardiovasc. Res., 28, 1713-1719.
4. BRADFORD, M.M. (1976). A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248-254.
5. BRISTOW, M.R. GINSBURG, R., MINOBE, W., CUBICIOTTI, R.S., SAGEMAN, W.S., LURIE, K., BILLINGHAM, M.E., HARRISON, D.C. & STINSON, E.B. (1982). Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N. Engl. J. Med., 307, 205-211.
6. DANIELSEN, W., VON DER LEYEN, H., MEYER, W., NEUMANN, J., SCHMITZ, W., SCHOLZ, H., STARBATTY, J., STEIN, B., DÖRING, V. & KALMÁR, P. (1989). Basal and isoprenaline-stimulated cAMP content in failing versus nonfailing human cardiac preparations. J. Cardiovasc. Pharmacol., 14, 171-173.
7. FELDMAN, A.M., CATES, A.E., VEAZEEY, W.B., HERSHBERGER, R.E., BRISTOW, M.R., BAUGHMAN, K.L., BAUMGARTNER, W.A. & VAN DOP, C. (1988). Increase in the 40,000-mol wt pertussis toxin substrate (G-protein) in the failing human heart. J. Clin. Invest., 82, 189-197.
8. FELDMAN, M.D. COPELAS, L., GWATHMEY, J.K., PHILLIPS, P. WARREN, S.E., SCHOEN, F.J., GROSSMAN, W. & MORGAN, J.P. (1987). Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation, 75, 331-339.
9. GWATHMEY, J.K., COPELAS, L., MACKINNON, R., SCHOEN, F.J., FELDMAN, M.D., GROSSMAN, W. & MORGAN, J.P. (1987). Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ. Res., 61, 70-76.
10. HONKANEN, R.E. (1993). Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A. FEBS Lett., 330, 283-286.
11. ISHIHARA, H., OZAKI, H., SATO, K., HORI, M., KARAKI, H., WATANABE, S., KATO, Y., FUSETANI, N., HASHIMOTO, K., UEMURA, D. & HARTSHORNE, D.J. (1989). Calcium-independent activation of contractile apparatus in smooth muscle by calyculin A. J. Pharmacol. Exp. Ther., 250, 388-396.
12. 2+ -ATPase activity in guinea pig ventricles. J. Biol. Chem., 258, 464-471.
13. LUO, W., GRUPP, I.L., HARRER, J., PONNIAH, S., GRUPP, G., DUFFY, J.J., DOETSCHMAN, T. & KRANIAS, E.G. (1994). Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of β-agonist stimulation. Circ. Res., 75, 401-409.
14. MACDOUGALL, L.K., JONES, L.R. & COHEN, P.K. (1991). Identification of the major protein phosphatases in mammalian cardiac muscle which dephosphorylate phospholamban. Eur. J. Biochem., 196, 725-734.
15. MUMBY, M.C., RUSSEL, K.L., GARRARD, L.J. & GREHN, D.D. (1987). Cardiac contractile protein phosphatases. J. Biol. Chem., 262, 6257-6265.
16. NEUMANN, J., BOKNIK, P., HERZIG, S., SCHMITZ, W., SCHOLZ, H., GUPTA, R.C. & WATANABE, A.M. (1993). Evidence of physiological functions of protein phosphatases in the heart. Evaluation with okadaic acid. Am. J. Physiol., 265, H257-266.
17. NEUMANN, J., GUPTA, R.C., SCHMITZ, W., SCHOLZ, H., NAIRN, A.C. & WATANABE, A.M. (1991). Evidence for isoproterenol-induced phosphorylation of phosphatase inhibitor-1 in the intact heart. Circ. Res., 69, 1450-1457.
18. NEUMANN, J., HERZIG, S., BOKNIK, P., APEL, M., KASPAREIT, G., SCHMITZ, W., SCHOLZ, H., TEPEL, M. & ZIMMERMANN, N. (1995). On the cardiac contractile, biochemical and electro-physiological effects of cantharidin, a phosphatase inhibitor. J. Pharmacol. Exp. Ther., 274, 530-539.
19. NEUMANN, J., SCHMITZ, W., SCHOLZ, H., VON MEYERNICK, L., DÖRING, V. & KALMÁR, P. (1988). Increase in myocardial Gi-proteins in heart failure. Lancet, ii, 936-937.
20. SHENOLIKAR, S. & NAIRN, A.C. (1991). Protein phosphatases: recent progress. In Advances in Second Messenger and Phosphoprotein Research, ed. Greengard, P. & Robison, G.A. pp. 1-121, New York.
21. 2-adrenoceptor-mediated positive inotropic effects in human end-stage heart failure. Br. J. Pharmacol., 105, 463-469.